Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFrom trial data to your fridge door: how tirzepatide actually works
What the SURMOUNT trials showed about tirzepatide and weight
The clearest place to start is the evidence. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults with obesity taking the highest dose lost roughly 20 to 21% of their body weight on average over 72 weeks, alongside a reduced-calorie diet and more activity. That study randomised 2,539 participants, so we're talking about thousands of adults, not a handful. The wider tirzepatide programme, combining the SURPASS diabetes trials with SURMOUNT, has enrolled well over 10,000 people.
More recently, the SURMOUNT-5 head-to-head trial compared tirzepatide directly against semaglutide 2.4mg over 72 weeks in 751 adults with obesity and no diabetes. Tirzepatide produced greater average weight reduction. That's a real finding, but it's an average across a trial population, not a promise for any one person. Results vary with dose, tolerance, and everything you do alongside treatment.
Those numbers matter because they're why the medicine is licensed and recommended at all. NICE reviewed the evidence and recommends tirzepatide for eligible adults, drawing on exactly this kind of data. If you want the plain-English version of the effectiveness picture, our page on Mounjaro for weight loss walks through it without the jargon. The trial figures are best read as "what happened on average in a controlled study," hedged accordingly, rather than a headline to bank on.
- You can read the patient-level summary on the NHS medicines page for tirzepatide.
What tirzepatide does in the body, in plain terms
Tirzepatide is a dual agonist, which is the part that makes it different. It switches on two receptors your gut naturally uses to signal to the brain: GIP and GLP-1. Most other weight-management injections act on GLP-1 alone. By hitting both pathways, tirzepatide dampens appetite, reduces food cravings and slows gastric emptying, so you feel full sooner and stay full longer. It also helps regulate blood sugar, which is why the same drug is licensed for type 2 diabetes too.
In practice, people describe the effect as the constant background hum of hunger going quiet. Portions that once felt normal start to feel like too much. That's the medicine working with your biology rather than relying on willpower, which matters, because weight is a health condition shaped by how your body regulates appetite, not a character flaw.
None of that happens instantly. The starter dose exists to let your system adjust and to keep early nausea manageable, not to drive weight loss on day one. The appetite effect builds as the dose steps up over the following weeks under a prescriber's guidance. If the mechanism interests you, we've explained it in more depth on how Mounjaro works. The short version: two hormone signals, one weekly injection, a slower and fuller stomach, and a quieter appetite.
Tirzepatide, Mounjaro and the naming confusion
A lot of the questions our prescribers hear most weeks come down to one thing: the naming. Tirzepatide is the generic (active-ingredient) name. Mounjaro is Eli Lilly's brand name for tirzepatide in the UK. They are the same medicine. If a page or seller talks about "tirzepatide" and "Mounjaro" as though they were rivals, that's a misunderstanding worth clearing up before you go any further.
We spell this out fully on whether tirzepatide is the same as Mounjaro, and there's a companion piece comparing the two names side by side at Mounjaro or tirzepatide. The naming matters for safety, too. Legitimate UK tirzepatide reaches you as branded Mounjaro through the licensed supply chain. Unbranded "tirzepatide" sold cheaply on social media, offered without a prescription or clinical assessment, is a red flag. The MHRA has warned about fake weight-loss pens sold online, and enforcement action in 2025 seized around 20 million doses of illegally traded weight-loss medicines, worth roughly £45m at street value.
So when you see the word tirzepatide in the wild, the sensible question isn't "is this the cheaper version of Mounjaro?" It's "is this coming from a pharmacy I can verify?" The GPhC register lets you check any UK online pharmacy in a minute. There's no separate, cut-price legal tirzepatide in Britain, just the licensed product under its brand name.
UK strengths and the weekly injection routine
Tirzepatide comes in six UK strengths: 2.5, 5, 7.5, 10, 12.5 and 15mg, delivered by a pre-filled KwikPen that holds four weekly doses. Treatment always begins at 2.5mg, which is a tolerability dose rather than a treatment dose, and a prescriber steps you up gradually, typically in four-week intervals, only when you're ready. Nobody starts at the top.
The injection goes under the skin of your abdomen, thigh or upper arm, and you rotate the site each week. It's once weekly on whichever day suits you, and many people find picking a fixed day, say a Sunday evening, makes it easy to remember. If you're weighing up timing, we've looked at the best time of day to take Mounjaro, though the honest answer is that consistency matters more than the exact hour.
Storage is straightforward but specific. Pens live in the fridge between 2 and 8°C, and there's a limited room-temperature window once you take them out. We won't print an exact number here, because it's the kind of detail you should confirm against the patient information leaflet supplied with your pen rather than a webpage. If needles make you nervous, you're far from alone, and the KwikPen is designed so you never see the needle before or during use. For dose-specific detail, pages like tirzepatide 10mg and tirzepatide 15mg cover individual strengths, but which one is right for you is a clinical decision, never a self-selection.
Who tirzepatide is licensed for, and who it isn't
The UK licence covers two uses: weight management and type 2 diabetes. For weight management, the licensed eligibility is broadly adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as prediabetes, high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance, usually by around 2.5 kg/m². BMI on its own never guarantees a prescription; a prescriber looks at your whole health picture.
Some people shouldn't take it. It isn't recommended in pregnancy, when breastfeeding, or if you're trying to conceive, and it isn't licensed for under-18s. A history of medullary thyroid cancer, MEN2 or pancreatitis, along with certain gut conditions, means a proper conversation with a prescriber before anything is decided. There's also a contraception point worth knowing: because tirzepatide can reduce how well oral contraceptives are absorbed, NHS guidance advises women using the pill to add a non-oral method, such as condoms, for the first four weeks and for four weeks after each dose increase.
Eligibility for private treatment differs from NHS access. On the NHS, tirzepatide is being rolled out in phases with strict criteria, and availability varies by GP practice and area. Privately, through a regulated online pharmacy, there's no waiting list and no referral, but the same clinical standards apply. If you want the practical route into treatment, our weight-loss treatments page is the starting point.
Side effects and the safety signals to take seriously
Most side effects are gastrointestinal and tend to show up when you start or step up a dose. Nausea is the common one, along with things like diarrhoea, constipation, indigestion, burping and the occasional headache or bout of tiredness. For most people these are at their most noticeable early on and often settle within a couple of weeks as the body adjusts. Eating smaller portions and going gently on rich or fatty food usually helps.
There's a more serious signal to know about. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines flagging acute pancreatitis: severe, persistent stomach pain that can spread through to your back, sometimes with vomiting. It's infrequent, but if that happens you should get urgent medical help. Other reasons to seek care promptly include signs of gallbladder trouble, an allergic reaction, or dehydration from heavy sickness or diarrhoea. We go into the abdominal symptoms in more detail on Mounjaro and stomach pain.
Because tirzepatide carries a Black Triangle (▼), the MHRA actively collects safety information on it, and anyone can report a suspected side effect through the Yellow Card scheme. That reporting system is also where you flag a suspect seller. None of this is meant to alarm you; it's the ordinary safety scaffolding around any newer prescription medicine. The point of a proper consultation, including checks before every repeat order, is that a clinician is watching for these signals alongside you rather than leaving you to spot them alone.
NHS access, private routes and the cost question
Tirzepatide is available on the NHS, but access is deliberately phased and the criteria are strict. Under the NICE recommendation (TA1026), the current NHS threshold is a BMI of 40 or above plus four or more qualifying conditions, with wider cohorts being brought in over the following months and years. From April 2026 GP practices could begin prescribing it under a new contract, though taking part is optional, so what's available depends heavily on your practice and local area. Every NHS patient also joins a wrap-around programme of diet and activity support.
If you don't meet those criteria, or you'd rather not wait, a regulated private pharmacy is the alternative. On cost: since Eli Lilly raised Mounjaro's UK list price in September 2025, typical private prices have ranged roughly £149 to £375 a month depending on dose and provider. Headline figures often leave out the extras, though: consultation fees, prescription charges, delivery and aftercare. At nume, one transparent price covers the consultation, the prescription, next-working-day delivery and seven-day aftercare, with no subscription and every repeat clinically reviewed. We're not the cheapest, and that's a deliberate choice. For a prescription medicine, the lowest listing answers the wrong question; a genuine supply chain and real clinical oversight are what actually keep you safe.
You can read the official position in NICE's recommendation on tirzepatide (TA1026), and if you want to see how our route works, getting Mounjaro online covers the practical steps.
Ready to find out whether it's suitable for you? Speak to our prescribers through a free consultation, and a real clinician, not software, reviews your answers the same day.
Related questions we've answered
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.